 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, announced today that abstracts on camidanlumab tesirine Cami and ZYNLONTATM loncastuximab tesirine-lpyl have been selected for presentation at the 16th Annual International Conference on Malignant Lymphoma ICML, which is being held virtually June 18-22, 2021. 